- LexaGene (LXG) is selling its MiQLab System to a veterinary hospital in southern California
- This is the first sale the company has closed, following Dr. Jane Sykes’ webinar on the utility of using the MiQLab System for diagnosing urinary tract infections
- The company is hitting the road again this month, with stops at trade shows in San Antonio, Texas and Nashville, Tennessee
- Lexagene Holdings Inc. (LXG) is trading steady at C$0.185 per share at 09:30 am ET
LexaGene (LXG) is selling its MiQLab System to a veterinary hospital in southern California.
LexaGene’s Founder and CEO, Dr. Jack Regan said this is the first sale the company has closed, following Dr. Jane Sykes’ webinar on the utility of using the MiQLab System for diagnosing urinary tract infections.
“We will continue to build momentum from this webinar as we demonstrate the value of the MiQLab System in our upcoming shows.”
The company is hitting the road again this month, with stops at trade shows in San Antonio, Texas and Nashville, Tennessee.
LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry.
Lexagene Holdings Inc. (LXG) is trading steady at C$0.185 per share at 09:30 am ET.
